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Background and purpose   Previous studies have shown that 
either fibrin spray or tranexamic acid can reduce blood loss at 
total hip replacement, but the 2 treatments have not been directly 
compared. We therefore conducted a randomized, controlled trial. 
Patients and methods   In this randomized controlled trial we 
compared the effect of tranexamic acid and fibrin spray on blood 
loss in cemented total hip arthroplasty. 66 patients were random-
ized to 1 of 3 parallel groups receiving (1) a 10 mg/kg bolus of 
tranexamic acid prior to surgery, (2) 10 mL of fibrin spray during 
surgery, or (3) neither. All participants except the surgeon were 
blinded as to treatment group until data analysis was complete. 
Blood loss was calculated from preoperative and postoperative 
hematocrit. 
Results   Neither active treatment was found to be superior to 
the other in terms of overall blood loss. Losses were lower than 
those in the control group, when using either tranexamic acid 
(22% lower, p = 0.02) or fibrin spray (32% lower, p = 0.02). 
Interpretation   We found that the use of tranexamic acid at 
induction, or topical fibrin spray intraoperatively, reduced blood 
loss compared to the control group. Blood loss was similar in the 
fibrin spray group and in the tranexamic acid group. 
ClinicalTrials.gov identifier: NCT00378872
EudraCT identifier: 2006-001299-19
Regional Ethics Committee approval: 06/S0703/55, granted June 
6, 2006 

Several different blood conservation methods have been 
adopted in lower limb arthroplasty. This study investigates 
the hemostatic effects of tranexamic acid and fibrin spray. The 
effects of these medications have been reported in isolation, 
but there have been few reports comparing their efficacy in the 
context of total hip replacement. 
Tranexamic acid is a synthetic amino acid that competi-
tively inhibits plasminogen, leading to reduced fibrinolysis 
locally (Ho and Ismail 2003). Fibrin spray is composed of 
active ingredients derived from human blood products, mainly 
fibrinogen and thrombin. These components are activated 
when mixed, forming fibrin which crosslinks directly with 
tissue collagen. Both of these therapies have been shown to 
be safe and effective in reducing blood loss in hip arthroplasty 
(Ho and Ismail 2003, Wang et al. 2003, Johansson et al. 2005). 
Differences in methodology between previous studies mean 
that it is difficult to draw comparisons between the two medi-
cations; such comparisons have not been widely reported in 
the context of cemented hip arthroplasty. 
We compared the effects of fibrin spray and tranexamic acid 
in cemented hip arthroplasty with total blood loss as the end-
point. We hypothesized that both treatments would have equal 
effectiveness.
Patients and methods
This was a prospective, single-center, multi-surgeon, single-
blind controlled trial with equal randomization. It was con-
ducted in the United Kingdom with approval from the West 
Glasgow Research Ethics Committee and the Medicines and 
Healthcare products Regulatory Agency, and it was performed 
in compliance with the Helsinki Declaration of 1975, as 
revised in 2000.
Patients were recruited June 2006 through May 2008. Each 
patient underwent a single joint replacement. Eligible patients 
were approached and given information sheets at preopera-Acta Orthopaedica 2011; 82 (6): 660–663  661
tive assessment clinics. Patients were eligible if they were 
scheduled to undergo elective primary unilateral cemented 
hip arthroplasty. They were excluded if they were taking anti-
coagulant medication or had a known coagulopathy, as such 
patients would have been predisposed to higher blood loss. 
Patients were also excluded if there were contraindications 
to giving the medications in the study: known allergy to the 
medications used, including allergy to aspirin; previous reac-
tion to blood products; ethical/religious objection to receiv-
ing blood products; or previous thromboembolism. Informed 
consent was obtained on admission to hospital. 4 patients who 
were assessed for eligibility were excluded because they were 
awaiting uncemented hip arthroplasty. 1 was excluded because 
there was no fibrin spray in stock on the day of the operation. 
The study protocol required that if patients were excluded 
because of protocol violations, they would be replaced by 
newly-recruited patients.
Patients were randomized to 1 of 3 treatment groups: (1) 
tranexamic acid (Cyklokapron; Meda Pharmaceuticals, UK), 
(2) fibrin spray (Quixil; Omrix Biopharmaceuticals, Belgium), 
or (3) neither (control). This was to assess the efficacy of each 
treatment against the other and against a control group, with 
total calculated blood loss as the endpoint. Patients were ran-
domized to treatment groups by use of opaque, sealed enve-
lopes. These were opened by the anesthetist immediately 
before anesthetic induction and they were not handled by the 
surgeon. This was a single-blind study: it was not possible to 
blind the surgeon to the application of the fibrin spray, as it cre-
ates a visible film on the operative wound when applied. The 
patients and all other staff involved in patient care remained 
blinded as to the treatment used. Blinding was maintained 
until statistical analysis of data, which was undertaken by an 
independent statistician. 
Criteria for stopping the study were the completion of data 
collection, or if any of the treatment groups were found to 
have a substantial increase in adverse clinical outcome(s) or 
rate of postoperative complications. 
Blood tests for full blood count, urea and electrolytes, 
clotting, and cross-match were obtained on admission. The 
patient’s weight, height, sex, and preoperative hematocrit 
were recorded. Each of the treatment groups had similar mean 
BMI and preoperative hematocrit (Table).
A standardized anesthetic was used in all cases, consist-
ing of combined regional anesthesia by epidural and general 
anaesthesia by target-controlled infusion of propofol. All hip 
replacements and data collection were performed at a single 
site (Golden Jubilee National Hospital, Clydebank, Scot-
land). A cemented Exeter hip prosthesis was used in all cases 
(Stryker Howmedica Osteonics, NJ). No drains were used. 
Patients randomized to the fibrin group received 10 mL of 
topical fibrin spray, given in divided doses throughout the 
operation. Patients in the tranexamic acid group were given 
a single 10 mg/kg dose of tranexamic acid as an intrave-
nous bolus at the start of the surgical procedure. All patients 
received the intended treatment to which they were allocated. 
A standard postoperative rehabilitation regime was used. 
All patients received standardized DVT prophylaxis as rec-
ommended by local guidelines at the time of the study. This 
included graduated compression stockings, early mobiliza-
tion, and 150 mg of aspirin by mouth for 35 days postopera-
tively. Hematocrit measurement was repeated on the second 
postoperative day. No patients were lost to follow-up and data 
collection was completed for all participants.
The patient’s total blood volume (PBV) was calculated, 
taking account of sex, height, and weight. Multiplication of 
PBV by hematocrit (Hct) will give total red cell volume in mL 
(Nadler 1962). Any change in red cell volume can therefore be 
calculated from the change in Hct. Any volume transfused or 
re-transfused is added to yield the true blood loss (Sehat et al. 
2004). This can be summarized by the formula:
True blood loss = ((PBV × change in Hct) / mean Hct ) + 
volume transfused
We used this method of calculation because it takes account 
of “hidden” losses (Sehat et al. 2004), e.g. postoperative hema-
toma formation (Benoni et al. 2001), which can be greatly 
underestimate when blood loss is recorded from suction drains 
or swabs (Sehat et al. 2004). 
Statistics
For calculation of power, we considered blood loss of 250 
mL to be a clinically significant amount. To detect this differ-
ence at 80% power and at the 5% significance level (α = 0.05) 
assuming an expected standard deviation (SD) of 290 mL for 
each group (Claeys et al. 2007), we required a sample size of 
22 patients per group. Recruitment continued until a total of 66 
patients were enrolled. Data for the 3 treatments (tranexamic 
acid, fibrin spray, control) were analyzed using the Kruskal-
Wallis test; pairwise comparisons were then performed using 
the Mann-Whitney U test. Analysis was performed with origi-
nally assigned groups of 22 patients per treatment group. Data 
were analyzed with Minitab software version 15 (Minitab 
Inc., State College, PA).
Results
No adverse outcomes were reported during the trial, so the 
trial ended when data collection was complete. Overall median 
intraoperative blood loss as measured from swabs and suction 
Patient data
  M  F  Hct (pre)  BMI
Control  9 13  0.40  28.49
Fibrin spray  5  17  0.40  28.02
Tranexamic  7 15  0.40  27.04
All  21 45  0.40  27.85662  Acta Orthopaedica 2011; 82 (6): 660–663
was 400 mL with an interquartile range (IQR) of 238 mL. One 
patient (in the fibrin spray group) was transfused with 2 units 
of packed red cells, and this was corrected for when calcu-
lating total blood loss. Calculated median total blood loss in 
the control group was 1.20 L (95% CI: 0.82–1.4; IQR: 0.50). 
Loss in the tranexamic acid group was median 0.93 L (CI: 
0.69–1.1; IQR: 0.35). In the fibrin spray group, median loss 
was 0.82 L (CI: 0.72–1.1; IQR: 0.33). 
There was a statistically significant difference in blood loss 
between the 3 groups (Kruskal-Wallis test, p = 0.02). On pair-
wise analysis (Mann-Whitney U test), when comparing the 
two active treatment agents against each other, there was no 
significant difference in blood loss (p = 1.0). However, the 
blood loss for tranexamic acid was significantly lower than 
for the control group (p = 0.02). Similarly, losses in the fibrin 
spray (p=0.02) treatment group were significantly lower than 
in the controls. Expressed as a percentage difference between 
median values, losses were 22% lower in the tranexamic group 
and 32% lower in the fibrin spray group (Figure). 
Discussion
Fibrin spray and tranexamic acid have both been reported to 
reduce blood loss in arthroplasty (Benoni et al. 2001, Ho and 
Ismail 2003, Husted et al. 2003, Johansson et al. 2005, Nis-
kanen and Korkala 2005, Mawatari et al. 2006, Rajesparan 
et al. 2009). Prior to the time of commencement of our study, 
each of the treatments had been used for some patients at the 
hospital where the study was conducted. 
Our method of blood loss calculation was chosen in light of 
previous work, which has demonstrated that measuring blood 
loss from swabs and suction drainage can lead to substantial 
underestimation of the actual loss (Sehat et al. 2004). Thus, we 
were not surprised to find that our calculated total blood losses 
were higher than those measured from swabs postoperatively. 
For this reason, we did not analyze the losses measured from 
swabs further, but used the more accurate calculated values. 
Tranexamic acid reduces blood loss by reducing local fibri-
nolysis, which is in turn caused by the activation of tissue 
plasminogen activator (Claeys et al. 2007). Previous stud-
ies have found that tranexamic acid reduces blood loss and 
transfusions following hip arthroplasty (Ho and Ismail 2003, 
Husted et al. 2003, Garneti and Field 2004, Johansson et al. 
2005, Niskanen and Korkala 2005, Rajesparan et al. 2009). It 
does not lead to an increase in the rates of deep venous throm-
bosis (Ho and Ismail 2003). It is relatively cheap and has been 
shown to be cost effective (Johansson et al. 2005). 
Fibrin spray is manufactured from human plasma products. 
It has been shown to be safe and effective in reducing blood 
loss and requirements for transfusion after hip arthroplasty 
(Wang et al. 2003, Mawatari et al. 2006). It is considerably 
costlier than tranexamic acid. The product is processed to 
remove pathogens and screened to detect contaminants, and 
has been fully approved and licensed for use in the UK. In 
common with any blood-derived treatment, there is a theo-
retical risk of transmission of disease by an unknown vector, 
a fact that was stated in our patient information sheet. We 
find it notable that some patients did not wish to participate 
in the study for this reason. Thus, if fibrin spray were to 
become widely used in orthopedic surgery, such risks should 
be included in the informed consent process. Also, in the geo-
graphic region in which this study was conducted, if fibrin 
spray has been used then patients are subsequently excluded 
from donating blood and bone. Fibrin sealants using autolo-
gous donated blood would remove these issues. Such sealants 
have been shown to be effective in reducing blood loss in hip 
arthroplasty (Mawatari et al. 2006) but at present they remain 
a rather specialist treatment. In common with many UK hos-
pitals, we do not have the facilities to prepare and use them. 
Interestingly, the Quixil fibrin spray contains tranexamic 
acid as one of its ingredients. Whilst the manufacturers state 
that its mechanism of action is due to the presence of human 
clotting factors, it is possible that the tranexamic acid is 
responsible for part of its action. To definitively answer this 
question would require a comparison of topically sprayed 
(rather than intravenous) tranexamic acid and topical fibrin 
spray, which was beyond the scope of this study. 
One important limitation of our study was the single-blind 
design. This was necessitated by the fact that we did not have 
a placebo for the fibrin spray. The manufacture and steriliza-
tion of a convincing placebo could not be achieved with the 
resources available. Also, the ethics committee had expressed 
concerns that any placebo preparation might expose patients 
to an unnecessary potential wound contaminant.
Patients in the fibrin group received 10 mL of topical fibrin 
spray, given in divided doses throughout the operation, which 
was the manufacturer’s recommended dose for this indication. 
Box plot of blood loss for each of the study groups (in mL), showing 
median, interquartile range (box), 5 and 95 percentiles (whiskers), and 
outliers.
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Patients in the tranexamic acid group were given a single 10 
mg/kg bolus dose of tranexamic acid intravenously, at induc-
tion of anesthesia. The manufacturer did not state a recom-
mended dose for this surgery, so our dose and timing was 
chosen on the basis of previous studies that have found a 10 
mg/kg bolus to be effective in hip arthroplasty when given at 
induction (Benoni et al. 2001, Garneti and Field 2004). While 
we confirmed the effectiveness of this dose in our study popu-
lation, it is worth noting that the same dose has been found 
to be ineffective if given at the end of surgery (Benoni et 
al. 2000). Some authors have reported giving a higher dose 
(Johansson et al. 2005, Claeys et al. 2007) or repeated doses 
(Ekbäck et al. 2000, Ido et al. 2000, Husted et al. 2003, Nis-
kanen and Korkala 2005), with the aim of prolonging the time 
at which the drug is maintained at its therapeutic plasma con-
centration.
When compared to control, both treatments were effective 
in THR—as we had hypothesized. This is consistent with pre-
vious literature regarding the use of either medication indi-
vidually (Benoni et al. 2001, Ho and Ismail 2003, Husted et 
al. 2003, Johansson et al. 2005, Niskanen and Korkala 2005, 
Mawatari et al. 2006, Rajesparan et al. 2009), although at the 
time of writing we are not aware of any previous direct com-
parison of both medications in THR. 
We conclude that in cemented total hip arthroplasty, blood 
loss was reduced by the use of either tranexamic acid or fibrin 
spray when compared to controls. Neither intervention was 
superior to the other. It is not possible to generalize the results 
in this study to uncemented hip arthroplasty or to arthroplasty 
of other joints. 
One area in which the two treatments differ greatly is their 
relative cost. The intravenous preparation of tranexamic acid 
(Cyklokapron) used in this study costs €1.80 per 5-mL (500-
mg) ampoule at the time of writing. The average patient weigh-
ing 70 kg, given a single 10 mg/kg dose, would receive 700 
mg at a cost of €3.60 (the unused 300 mg being discarded). 
In contrast, the current price of the fibrin spray (Quixil) prepa-
ration is €450. Given the equivalent effects of both medica-
tions in this study, together with the cost considerations and 
theoretical harms from the use of blood-derived products, it 
would seem prudent to use tranexamic acid in preference to 
fibrin spray. 
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